Suicide is one of the leading causes of death worldwide. According to the World Health Organization (WHO), every year, more than 700 thousand people die from this cause. Therefore, suicide is a public health issue. The complex interaction between different factors causes suicide; however, depression is one of the most frequent factors in people who have attempted suicide. Several studies have reported that vitamin D deficiency may be a relevant risk factor for depression, and vitamin D supplementation has shown promising effects in the adjunctive treatment of this mood disorder. Among the beneficial mechanisms of vitamin D, it has been proposed that it may enhance serotonin synthesis and modulate proinflammatory cytokines since low serotonin levels and systemic inflammation have been associated with depression and suicide. The present narrative review shows the potential pathogenic role of vitamin D deficiency in depression and suicide and the potential benefits of vitamin D supplementation to reduce their risk.

Despite the high rates of discrimination and mental health issues experienced by lesbian, gay, bisexual, and transgender (LGBT) adults at an international level, very little research has focused on this population in Latin America. As a result, the purpose of this study was to explore relationships among discrimination experiences, mental health (i.e., anxiety and depressive symptoms), suicidal ideation, religiosity, and social support in LGBT adults in Latin America. A sample of 99 participants from the region completed an online survey assessing these constructs. Results suggested that 51.5% of the sample reported lifetime suicidal ideation. Experiences with harassment/rejection-type discrimination predicted suicidal ideation, while work/school-type discrimination predicted mental health problems (anxiety and depression). Depressive symptoms predicted suicidal ideation, while anxiety symptoms alone did not. Further, depressive symptoms mediated relationships between work/school discrimination and suicidal ideation, as well as between harassment/rejection discrimination and suicidal ideation. Moderated mediation analyses suggested that high, but not low or moderate levels of social support and religiosity buffered LGBT adults in Latin America against discrimination, specifically by weakening links among discrimination, depressive symptoms, and suicidal ideation. Clinical intervention research with LGBT adults in Latin America should focus on increasing social support networks for this population and on helping LGBT adults reconcile conflicts between religious identities and sexual or gender minority identities, as healthy religiosity may serve as a protective factor against mental health problems generally, and suicidal ideation specifically.

Cognition is a set of brain processes that allow the individual to interact with their environment. Multiple sclerosis (MS) is a chronic inflammatory disease that affects the cerebral white matter of the brain cortex and spinal cord, leading to cognitive impairment (CI) in 40–60% of the patients. Many studies have determined that CI is linked to genetic risk factors. We aimed to evaluate the association between BDNF gene rs6265 polymorphism and cognitive impairment in Mexican patients with MS by performing a case–control study. Mestizo-Mexican patients diagnosed with MS based on McDonald’s criteria were enrolled. Cases were MS patients with CI (n = 31) while controls were MS patients without CI (n = 31). To measure cognitive functioning in MS patients, a neuropsychological screening battery for MS (NSB-MS) was used. Genotyping of the rs6265 gene variant was performed using quantitative real-time PCR (qPCR) with TaqMan probes. The results showed no statistically significant differences in sociodemographic and disease variables between case and control groups. qPCR analysis showed that there were 68% Val/Val wild-type homozygotes, 29% Val/Met polymorphic heterozygotes, and 3% Met/Met polymorphic homozygotes. The presence of BDNF gene rs6265 polymorphism showed an increased probability (3.6 times) of global cognitive impairment.

Background: Methamphetamine (MA) use in people living with HIV (PLWH) has been linked to neurocognitive and behavioral dysregulation. We hypothesized that PLWH with active MA use (MAHIV) would show poorer cognitive performance, greater emotional and sleep burden, higher behavioral risk, and alterations in circulating biomarkers of immune activation and neuronal injury, relative to PLWH without MA use and HIV-negative Controls. Methods: Cross-sectional analytic study of 121 adults: PLWH with MA use (MAHIV, n = 40), PLWH without use (n = 42), and HIV-negative Controls (n = 39). Outcomes were ART discontinuation, physical activity, neurocognition (MoCA), depression (BDI), anxiety (GAD-7), sleep (PSQI), and substance use (ASSIST). Circulating biomarkers measured by ELISA: sCD14, neuron-specific enolase (NSE), S100B, and neurofilament light chain (NfL). Results: MAHIV participants had more frequent ART discontinuation than PLWH and the lowest physical activity. Chemsex with polysubstance use, condomless sex, and multiple partners were most prevalent in MAHIV. This group showed the highest anxiety and depressive burdens, and the greatest sleep disturbances. Global cognition (MoCA) was lowest in MAHIV, with significant deficits in executive function, memory, attention, and language; 82.5% had at least mild cognitive impairment. sCD14 was significantly higher in MAHIV than in PLWH and Controls, and NSE was elevated in both MAHIV and PLWH versus Controls. sCD14 correlated inversely with MoCA and positively with GAD-7 and BDI-II. Conclusions: Among PLWH, MA use is associated with greater ART nonadherence, syndemic mental-health and sleep disturbances, broader neurocognitive deficits, and elevations in circulating sCD14 and NSE. The sCD14–cognition and sCD14–mood relationships highlight chronic immune activation as a candidate pathway for neurocognitive and affective impairment and support sCD14 and NSE as potential stratification and monitoring biomarkers in MA-using PLWH.

Multiple sclerosis (MS) is a chronic, autoimmune pathology that affects the nervous system. It is characterized by inflammatory lesions that cause axonal damage with neurodegeneration. The signs and symptoms present in this pathology include among others, psychiatric disorders. In MS, depression is the most frequent psychiatric disorder, with prevalence levels of 40 to 60%; to date, the cause is unknown. The brain-derived neurotrophic factor (BDNF) is a neurotrophin related to neuroplasticity. The single-nucleotide polymorphism Val66Met, encoded by the BDNF gene, has been associated with various effects, including the presence of neuropsychiatric disorders. The purpose of our study was to evaluate the association between the BDNF Val66Met polymorphism and depression in MS patients. Methods: Study design, cases, and controls: Mexican mestizo MS patients. Cases: Patients diagnosed with depression. Controls: Patients without depression diagnosis. Measurements: For depression, the Beck Depression Inventory; for polymorphism, real-time PCR. Results: No statistically significant differences were found in sociodemographic and disease variables between the case and control groups. qPCR analysis showed that 68% of the participants were Val/Val wild-type homozygotes, 29% were Val/Met polymorphism heterozygotes, and 3% were Met/Met polymorphism homozygotes. The presence of the BDNF gene rs6265 polymorphism was associated with a 5.6-fold increase in the probability of depression in the cases compared to the controls. Conclusions: The BDNF Val66Met Polymorphism is associated with depression in Mexican mestizo patients diagnosed with MS.

Background: Multiple Sclerosis (MS) is an inflammatory, autoimmune and neurodegenerative disease of the central nervous system that leads to the progressive loss of motor and sensory functions. Cognitive dysfunction is a common symptom that significantly affects quality of life and daily activities. The MS diagnosis involves progressive disability due to its neurodegenerative nature. Objective: to analyze the relationship between the Latin Norm Neuropsychological Assessment and Disability in Multiple Sclerosis (NLNAMS) battery and physical disability in patients with MS. Methods: A retrospective review of 100 medical records was conducted. Three sections of clinical information were analyzed: (1) sociodemographic data and medical history, (2) neurological examination including disability measures using the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Severity Score (MSS), and (3) neuropsychological assessment results obtained through the NLNAMS battery to evaluate cognitive functioning across multiple domains. Results: High correlations were observed between EDSS scores and performance on the Symbol Digit Modalities Test (SDMT) and the Hopkins Verbal Learning Test–Revised (HVLT-R), which assess attention, processing speed and memory. Strong correlations were also found between EDSS and performance on verbal fluency tests, Trail Making Test (TMT), Rey–Osterrieth Complex Figure copy (ROCF), and the Modified Wisconsin Card Sorting Test (M-WCST). No significant correlation with MSS was found. Conclusions: The neuropsychological evaluation conducted with the NLNAMS battery showed a relationship between physical disability in multiple sclerosis and the domains of attention, processing speed, and memory. Therefore, this battery may provide valuable information for disease monitoring and prognosis.